Effects of selegiline, phenylpropanolamine, or a combination of both on physiologic and behavioral variables in healthy dogs

American Journal of Veterinary Research

Volumn 63, Issue 6, 2002, Pages 827-832

  Cohn, Leah A ^a   Dodam, John R ^a   Szladovits, Balazs ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHENYLPROPANOLAMINE; SELEGILINE; ADRENERGIC RECEPTOR STIMULATING AGENT; MONOAMINE OXIDASE INHIBITOR;

ANALYSIS OF VARIANCE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BREATHING RATE; CONTROLLED STUDY; DOG; DRUG EFFECT; ELECTROCARDIOGRAM; NONHUMAN; OSCILLOMETRY; PULSE RATE; RATING SCALE; RECTUM TEMPERATURE; ANIMAL; ANIMAL DISEASE; BLOOD PRESSURE; BODY TEMPERATURE; BREATHING; DRUG COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; MALE; METABOLISM; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZATION;

ANIMALIA; CANIS FAMILIARIS;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD PRESSURE; BODY TEMPERATURE; DOGS; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; MALE; MONOAMINE OXIDASE INHIBITORS; PHENYLPROPANOLAMINE; PULSE; RANDOM ALLOCATION; RESPIRATION; SELEGILINE; SYMPATHOMIMETICS;

EID: 0036017302     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2002.63.827     Document Type: Article

References (30)

1. Monoamine oxidase inhibitors. An update on drug interactions
2. Drug interactions of clinical significance with selective serotonin reuptake inhibitors
3. Monoamine oxidase and catechol-O-methyltransferase inhibitors
4. CVT update: L-deprenyl in the treatment of canine pituitary-dependent hyperadrenocorticism
5. A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting
6. The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog
7. Hyperadrenocorticism (Cushing's syndrome)
8. Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: Clinical presentation, cognitive testing, pathology and response to L-deprenyl therapy
9. Clinical manifestations of urinary disorders
10. Cough and cold remedies: A potential danger to patients on monoamine oxidase inhibitors
11. Uropharmacology: VIII. Sympathomimetic agents
12. Cardiovascular studies of phenylpropanolamine
13. The effect of phenylpropanolamine on the urethral pressure and heart rate is retained after repeated short-term administration in the unanaesthetized, conscious dog
14. Adrenergic agonists and antagonists
15. Nervous regulation of the circulation, and rapid control of arterial pressure
16. Cerebral vasculitis and hemorrhage associated with phenylpropanolamine
17. Adverse drug effects attributed to phenylpropanolamine: A review of 142 case reports
18. Phenylpropanolamine and the risk of hemorrhagic stroke
19. The effect of phenylpropanolamine on ambulatory blood pressure
20. Phenylpropanolamine and blood pressure: A review of prospective studies
21. The effect of phenylpropanolamine on 24-hour blood pressure in normotensive subjects administered indomethacin
22. Comparison of effects of two dosage regimens of phenylpropanolamine on blood pressure and plasma levels in normal subjects under steady-state conditions
23. The effects of phenylpropanolamine hydrochloride in overweight patients with controlled stable hypertension
24. The safety of phenylpropanolamine in patients with stable hypertension
25. MAOIs and hypertensive crises: The role of OTC drugs
26. On the substrate specificities of the two forms of monoamine oxidase
27. Spatial learning and memory as a function of age in the dog
28. Amphetamine-like reactions to phenylpropanolamine